| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Sep 01, 2020 |
Chief Financial Officer
Trans History: 14
|
Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 225,000 | -- | 225,000 |
| Oct 01, 2018 |
Chief Financial Officer
Trans History: 5
|
Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 59,590 | -- | 59,590 |
| Aug 21, 2018 |
Chief Financial Officer
Trans History: 5
|
Chief Financial Officer | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- |
| Aug 21, 2018 |
Chief Financial Officer
Trans History: 5
|
Chief Financial Officer | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- |
| Aug 21, 2018 |
Chief Financial Officer
Trans History: 5
|
Chief Financial Officer | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- |
| Dec 30, 2021 |
Chief Informatics Officer
Trans History: 1
|
Chief Informatics Officer | Form 5 | Bona fide gift | 318,899 | -- | 5,006,479 |
| Sep 18, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 20,000 | -- | 144,794 |
| Sep 18, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 40,000 |
| Feb 15, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 120,000 | -- | 124,794 |
| Feb 15, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 560,000 | -- | 560,000 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.